Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor

  • Bioorg Med Chem Lett. 2005 Mar 1;15(5):1401-5. doi: 10.1016/j.bmcl.2005.01.003.
Joseph L Duffy  1 ,  Brian A Kirk ,  Zenon Konteatis ,  Elizabeth L Campbell ,  Rui Liang ,  Edward J Brady ,  Mari Rios Candelore ,  Victor D H Ding ,  Guoqiang Jiang ,  Frank Liu ,  Sajjad A Qureshi ,  Richard Saperstein ,  Deborah Szalkowski ,  Sharon Tong ,  Lauri M Tota ,  Dan Xie ,  Xiaodong Yang ,  Peter Zafian ,  Song Zheng ,  Kevin T Chapman ,  Bei B Zhang ,  James R Tata
Affiliations
  • 1. Department of Basic Chemistry, Merck Research Laboratories, Rahway, NJ 07065, USA. [email protected]
PMID: 15713396 DOI: 10.1016/j.bmcl.2005.01.003
Abstract

A novel class of antagonists of the human Glucagon Receptor (hGCGR) has been discovered. Systematic modification of the lead compound identified substituents that were essential for activity and those that were amenable to further optimization. This SAR exploration resulted in the synthesis of 13, which exhibited good potency as an hGCGR functional antagonist (IC50 = 34 nM) and moderate bioavailability (36% in mice).